Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
Source: View publication →
In patients with vascular disease or high-risk diabetes without heart failure, the angiotensin-receptor blocker telmisartan is non-inferior to the ACE inhibitor ramipril, but combining the two drugs increases adverse events without providing additional cardiovascular benefit.
Key Findings
Study Design
Study Limitations
Clinical Significance
ONTARGET firmly established ARBs (like telmisartan) as a safe, equally efficacious alternative to ACE inhibitors (like ramipril) for cardiovascular risk reduction in high-risk patients, making them the preferred choice for patients who develop ACE-inhibitor-induced cough or angioedema. Crucially, the trial debunked the 'dual blockade' hypothesis, demonstrating that combining an ACE inhibitor and an ARB is harmful—leading to increased renal failure and hypotension without any added cardiovascular protection.
Historical Context
Following the landmark HOPE trial (2000), which proved that the ACE inhibitor ramipril significantly reduced cardiovascular events in high-risk patients, ACE inhibitors became the gold standard of care. Meanwhile, ARBs were emerging as better-tolerated alternatives. At the time, researchers hypothesized that dual blockade of the renin-angiotensin-aldosterone system (RAAS) by combining an ACE inhibitor and an ARB might provide additive protective effects by more completely suppressing angiotensin II. ONTARGET was designed to conclusively answer whether telmisartan was non-inferior to ramipril, and whether combination therapy was superior.
Guided Discussion
High-yield insights from every perspective
What is the pathophysiological rationale for why combining an ACE inhibitor and an angiotensin-receptor blocker (ARB) was initially hypothesized to provide additive cardiovascular benefits, and why did the ONTARGET trial disprove this for clinical outcomes?
Key Response
ACE inhibitors block the conversion of angiotensin I to II but allow escape pathways (like chymase) to produce AT II, while ARBs block the AT1 receptor directly but do not prevent bradykinin breakdown. It was hypothesized that dual blockade would completely eliminate AT II effects while maximizing bradykinin-mediated vasodilation. However, ONTARGET showed this dual blockade did not improve CV outcomes but significantly increased the risk of hyperkalemia, hypotension, and acute kidney injury due to a profound reduction in glomerular efferent arteriolar tone.
Based on the ONTARGET trial results, how should a physician manage a patient with high-risk type 2 diabetes and coronary artery disease who develops a chronic dry cough while on ramipril?
Key Response
The trial demonstrated that telmisartan is non-inferior to ramipril for reducing the risk of cardiovascular death, myocardial infarction, and stroke in high-risk patients, with significantly lower rates of cough and angioedema. Therefore, the resident should discontinue ramipril and confidently substitute it with telmisartan (or an equivalent ARB) without concern for a loss of cardiovascular protection.
The ONTARGET trial utilized telmisartan, an ARB known for its exceptionally long half-life and partial PPAR-gamma agonist activity. To what extent can the non-inferiority results of telmisartan compared to ramipril be considered a class effect for all ARBs in cardiovascular risk reduction?
Key Response
Telmisartan has unique pharmacokinetic properties, including high lipophilicity, a 24-hour half-life ensuring continuous BP control, and potential metabolic benefits via PPAR-gamma agonism. While other trials (like VALIANT in post-MI patients) support ARB non-inferiority, extrapolating ONTARGET's exact magnitude of benefit to shorter-acting ARBs like losartan requires caution, as strict 24-hour ambulatory blood pressure coverage is critical for mitigating early-morning vascular events.
How does the failure of the dual-therapy arm in the ONTARGET trial serve as a critical teaching point regarding the pharmacodynamic fallacy of 'more is better' and the danger of relying on surrogate endpoints in neurohormonal blockade?
Key Response
The trial elegantly illustrates that aggressively targeting a single physiological axis (RAAS) in patients without clinical heart failure hits a ceiling of efficacy while exponentially increasing toxicity. It reinforces the principle of relying on hard clinical endpoints, as dual therapy actually lowered blood pressure and proteinuria (surrogate markers) more than monotherapy, yet worsened overall clinical outcomes, warning attendings against over-titrating based on numbers alone.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ONTARGET trial utilized a non-inferiority design to compare telmisartan with ramipril, retaining a prespecified fraction of the ramipril effect established in the historical HOPE trial. What are the methodological challenges of defining a non-inferiority margin based on historical placebo-controlled data, and how does the constancy assumption impact the trial's internal validity?
Key Response
Defining the margin requires the 'constancy assumption'--that the active control (ramipril) has the same effect magnitude in the current trial as it did in the historical HOPE trial. Methodological challenges arise because background therapies (like statins and antiplatelets) improved significantly between HOPE and ONTARGET, potentially shrinking the true effect size of the control. If the control performs worse than historically observed, the experimental drug might falsely appear non-inferior (biocreep), necessitating rigorous statistical adjustment.
Given that blood pressure reductions were marginally but significantly greater in the telmisartan and combination groups compared to the ramipril group in the ONTARGET trial, how should an editor evaluate whether the observed outcomes were confounded by blood pressure differences rather than drug-specific mechanisms?
Key Response
A critical reviewer must scrutinize whether the slight BP reduction differences (approximately 1/1 mmHg) confounded the primary endpoints. The editor must assess if the non-inferiority of telmisartan was partially due to slightly better BP control masking a weaker pleiotropic effect compared to ramipril. In the combination arm, the lack of CV benefit despite lower BP highlights that adverse off-target effects of dual RAAS blockade completely negated any hemodynamic advantage.
How did the results of the ONTARGET trial specifically alter international cardiovascular prevention guidelines regarding the simultaneous use of ACE inhibitors and ARBs, and what level of evidence was assigned to this practice change?
Key Response
Prior to ONTARGET, dual RAAS blockade was sometimes used to aggressively manage proteinuria or refractory hypertension. Following the trial's finding of increased renal impairment, hyperkalemia, and hypotension without CV benefit, guidelines (such as the ACC/AHA and ESC/ESH hypertension guidelines) explicitly contraindicated the routine combination of ACE inhibitors and ARBs. This was universally assigned a Class III (Harm) recommendation with Level of Evidence A, fundamentally changing clinical practice paradigms.
Clinical Landscape
Noteworthy Related Trials
HOPE Trial
Tested
Ramipril 10 mg daily
Population
Patients at high risk for cardiovascular events
Comparator
Placebo
Endpoint
Composite of cardiovascular death, myocardial infarction, or stroke
VALIANT Trial
Tested
Valsartan, captopril, or a combination of both
Population
Patients with heart failure or left ventricular dysfunction following acute myocardial infarction
Comparator
Active comparators
Endpoint
All-cause mortality
TRANSCEND Trial
Tested
Telmisartan 80 mg daily
Population
Patients with high cardiovascular risk who are intolerant to ACE inhibitors
Comparator
Placebo
Endpoint
Composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis